Employees
35
Industry
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
there is an unmet need for new treatments for autoimmune diseases that transform paradigms and clinical practice. landos will address that unmet clinical need. we know physicians are tired of settling for mediocre therapies for patients living with autoimmune disorders. with one first in class, oral therapy for inflammatory bowel disease (ibd) and its two clinical manifestations: crohn’s disease and ulcerative colitis, showing remarkable preclinical results and entering clinical trials, our team is poised to soon offer ibd patients a better way. the bottom line is this: patients deserve treatment options that are safer, more effective, and less disruptive to their lives. that is what drives landos scientists and our team each and every day.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Vandana Singh
April 26, 2024 | 1:54 pm
Portfolio Pulse from Benzinga Newsdesk
April 01, 2024 | 11:12 am
Portfolio Pulse from Avi Kapoor
March 25, 2024 | 7:00 pm
Portfolio Pulse from Benzinga Insights
March 25, 2024 | 5:31 pm
Portfolio Pulse from Avi Kapoor
March 25, 2024 | 4:07 pm
Portfolio Pulse from Vandana Singh
March 25, 2024 | 4:06 pm
Portfolio Pulse from Benzinga Newsdesk
March 25, 2024 | 4:04 pm
Portfolio Pulse from Avi Kapoor
March 25, 2024 | 1:42 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.